Biologics Market Size & Growth Forecast 2027–2036, By Segments (Manufacturing, Source, Product, Disease Category), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Biologics Market size was worth USD 691.1 billion in 2026 and is expected to grow at a 9.22% CAGR between 2027 and 2036, exceeding USD 1.67 trillion by 2036. The industry revenue for 2027 is calculated at USD 744.73 billion.

• Base Year Value (2026): USD 691.1 billion
• CAGR (2027-2036): 9.22%
• Forecast Year Value (2036): USD 1.67 trillion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Biologics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to strong biopharmaceutical ecosystem, large-scale manufacturing capacity, rapid commercialization pathways, and high biologics adoption in specialty care settings.
  • Asia Pacific growth is driven by expanding biopharmaceutical production, rising adoption of advanced therapies, improved healthcare access, and increasing biologics manufacturing capabilities.

• Segment Momentum:

  • In-house manufacturing held an 80.63% share in 2026 as companies prioritize direct control over production quality, process consistency, proprietary expertise, and commercial supply coordination.
  • Mammalian sources are expanding fastest because they better support the production of increasingly complex biologic products requiring advanced expression systems and greater biological compatibility.

• Market Expansion Drivers:

  • Rising prevalence of cancer and autoimmune disorders increasing biologic therapy demand.
  • Expansion of personalized medicine and companion diagnostics accelerating targeted biologic adoption.
  • Growing commercialization of mRNA and gene therapies strengthening advanced biologics innovation pipelines.

• Leading Market Participants:

  Key companies in the biologics market include Samsung BioLogics Co., Ltd. (South Korea), Amgen Inc. (United States), Novo Nordisk A/S (Denmark), AbbVie Inc. (United States), Sanofi S.A. (France), Johnson & Johnson (United States), Celltrion Inc. (South Korea), Bristol-Myers Squibb Company (United States), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd (Switzerland).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 691.1 billion
  • 2027 Estimated Market Size: USD 744.73 billion.
  • Projected Market Size: USD 1.67 trillion by 2036
  • Growth Forecasts: 9.22% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: In-house (Manufacturing) | Microbial (Source) | Monoclonal Antibodies (Product) | Oncology (Disease Category)
  • Emerging Opportunity Segment: Outsourced (Manufacturing) | Mammalian (Source) | Antisense & RNAi Therapeutics (Product) | Hematological Disorders (Disease Category)

Market Growth Drivers and Industry Trends

Rising prevalence of cancer and autoimmune disorders increasing biologic therapy demand

The increasing burden of cancer and autoimmune disorders is creating greater demand for therapies capable of addressing complex disease mechanisms with greater specificity. Rising treatment needs will drive the biologics market as biologic medicines, including antibodies, recombinant proteins, and other advanced therapies, are increasingly incorporated into treatment strategies for conditions where conventional medicines may provide limited outcomes. Growing recognition of targeted biological mechanisms and continued development of disease-specific therapies are also expanding treatment options for patients with chronic and difficult-to-manage disorders.

Expansion of personalized medicine and companion diagnostics accelerating targeted biologic adoption

The shift toward personalized medicine is enabling healthcare providers to select therapies based on individual patient characteristics, disease biology, and treatment response. Companion diagnostics will propel the biologics market by helping identify patients who are more likely to benefit from specific targeted therapies, improving treatment selection and supporting more precise clinical decision-making. Advances in biomarker identification and molecular testing are also strengthening the connection between diagnostic information and therapeutic development, encouraging the use of biologics designed around defined patient populations and disease pathways.

Growing commercialization of mRNA and gene therapies strengthening advanced biologics innovation pipelines

The commercialization of mRNA and gene-based treatments is broadening the scope of biological medicine beyond established therapeutic platforms. The biologics market is gaining from investment in these advanced modalities as researchers and manufacturers develop approaches capable of modifying disease pathways, delivering therapeutic genetic information, or addressing underlying biological mechanisms. Progress in delivery technologies, manufacturing processes, and clinical development is helping expand the range of applications for next-generation therapies, while mRNA and gene-based approaches are becoming increasingly integrated into broader biologics development strategies.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising prevalence of cancer and autoimmune disorders increasing biologic therapy demand	2.00%	High	North America, Europe	High	Near Term
Expansion of personalized medicine and companion diagnostics accelerating targeted biologic adoption	1.80%	High	North America, Asia Pacific	High	Mid Term
Growing commercialization of mRNA and gene therapies strengthening advanced biologics innovation pipelines	1.50%	High	North America, Europe	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

In the biologics market, North America held the largest share at 47.03% in 2026, supported by advanced biopharmaceutical research capabilities, well-developed healthcare infrastructure, and strong demand for innovative therapies. The region benefits from substantial investment in biologics development, sophisticated manufacturing and clinical research ecosystems, and broad access to specialized healthcare services. Growing adoption of targeted and personalized treatments, together with established regulatory and reimbursement frameworks, continues to reinforce the region's commercial position. Strong integration between research institutions, healthcare providers, and biopharmaceutical manufacturing also supports sustained demand for complex biologic therapies.

Asia Pacific is positioned as the fastest-growing region, driven by expanding healthcare access, rising investment in biopharmaceutical manufacturing, and increasing demand for advanced therapeutic options. Improvements in healthcare infrastructure and the gradual strengthening of local research and production capabilities are creating a broader foundation for biologics adoption. Growing patient populations, increasing awareness of innovative treatments, and efforts to expand domestic pharmaceutical capacity are further supporting market development. In addition, the expansion of clinical research and technology transfer is helping regional markets strengthen their participation across the biologics value chain.

Key Country Insights

United States

Advanced Biopharma Development

The U.S. biologics market benefits from extensive research activity, established manufacturing capabilities, and strong demand for innovative therapies. Companies continue expanding production capacity while strengthening development pipelines for complex biologic medicines.

Japan

Specialized Therapeutic Focus

Japan prioritizes biologic therapies that address complex medical conditions through continuous research and clinical development. Companies strengthen manufacturing capabilities while supporting innovation across next-generation biologic treatment platforms.

South Korea

Biomanufacturing Expansion

South Korea continues expanding biologics manufacturing capacity while enhancing capabilities across contract development and production services. The market supports investment in advanced processing technologies and efficient large-scale biologic manufacturing.

Germany

Precision Manufacturing Excellence

Germany's biologics market emphasizes high-quality manufacturing, process optimization, and compliance with rigorous production standards. Biopharmaceutical companies invest in advanced production technologies to support reliable supply and specialized therapeutic development.

France

Clinical Research Integration

France combines biologics development with strong clinical research activity and advanced healthcare collaboration. Companies focus on accelerating therapeutic innovation while maintaining high standards for manufacturing quality and regulatory compliance.

Italy

Production Capability Enhancement

Italy is strengthening biologics manufacturing and specialized pharmaceutical production to support growing therapeutic demand. Market participants emphasize process efficiency, quality assurance, and collaborative development across the biologics value chain.

Segment Leadership and Growth Trends

 

Manufacturing Segment Analysis: In-house (Largest Segment) vs Outsourced (Fastest-Growing Segment)

In-house manufacturing held the largest share of the biologics market in 2026, reflecting the strategic importance of maintaining direct control over biologics production, quality management, and manufacturing processes. Internal capabilities allow organizations to closely manage critical production parameters, protect proprietary processes, and coordinate manufacturing with research and development activities. The need for stringent quality oversight and reliable supply of complex biologic products continues to support investment in dedicated manufacturing infrastructure.

Outsourced manufacturing is the fastest-growing segment as biologics developers increasingly seek specialized production capabilities without assuming the full cost and operational complexity of expanding internal facilities. External manufacturing partners can provide access to specialized expertise, flexible production capacity, and established quality systems, enabling organizations to focus more closely on drug development and commercialization activities. Growing biologics complexity and the need for scalable manufacturing solutions are strengthening the strategic role of outsourcing across the value chain.

Source Segment Analysis: Microbial (Largest Segment) vs Mammalian (Fastest-Growing Segment)

The microbial segment represented the largest share of the biologics market in 2026, supported by the established use of microbial systems for producing biologic substances and other complex biomolecules. Microbial platforms can offer efficient cultivation, comparatively straightforward process management, and suitability for applications where microbial expression systems can meet production requirements. Their established manufacturing workflows and broad utility continue to make microbial sources an important part of biologics production.

Mammalian is the fastest-growing source segment, driven by its importance in producing biologics that require complex protein structures and post-translational modifications. Mammalian expression systems are particularly valuable for advanced therapeutic products where biological activity and molecular characteristics depend on sophisticated cellular processing. As demand for complex biologics expands, increasing attention to product quality, structural fidelity, and therapeutic performance is supporting greater adoption of mammalian-based production systems.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Manufacturing	Outsourced, In-house	In-house	Outsourced
Source	Microbial, Mammalian, Others	Microbial	Mammalian
Product	Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense & RNAi Therapeutics, Others	Monoclonal Antibodies	Antisense & RNAi Therapeutics
Disease Category	Oncology, Infectious Diseases, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, Others	Oncology	Hematological Disorders

Competitive Landscape and Market Positioning

Key companies in the biologics market:

1. Samsung BioLogics Co. Ltd. (South Korea)

2. Amgen Inc. (United States)

3. Novo Nordisk A/S (Denmark)

4. AbbVie Inc. (United States)

5. Sanofi S.A. (France)

6. Johnson & Johnson (United States)

7. Celltrion Inc. (South Korea)

8. Bristol-Myers Squibb Company (United States)

9. Eli Lilly and Company (United States)

10. F. Hoffmann-La Roche Ltd (Switzerland)

The biologics market is advancing through continuous innovation in complex therapeutic development. Increasing focus on targeted therapies is improving treatment outcomes for chronic and rare diseases. Ongoing research activity is strengthening drug pipelines, while expanding biotechnology ecosystems are supporting faster development and commercialization of biologic treatments.

Industry Development/News

Company Name	Date	Key Development
Samsung Biologics	Jan-26	Samsung Biologics entered the U.S. manufacturing market through a $280 million acquisition of a facility in Maryland. This expansion of its global network strengthens the company's regional biologics production capabilities and competitive positioning in North America.
Lonza	Oct-24	Lonza finalized the $1.2 billion acquisition of Roche’s Vacaville biologics manufacturing facility in California. This strategic move significantly increases the company's mammalian biologics production capacity, addressing the growing demand for large-scale contract manufacturing in the U.S. market.
Bora Pharmaceuticals	May-26	Bora Pharmaceuticals entered a definitive agreement to acquire MacroGenics’ manufacturing facility and CDMO operations for up to $127.5 million. The acquisition serves to broaden the company’s biologics manufacturing footprint and enhance its integrated contract development and manufacturing service offerings.
Sanofi	Nov-24	Sanofi commissioned a $590 million modular manufacturing facility in Singapore. The site is engineered for high operational flexibility, enabling rapid production switching between vaccines and biologic medicines to support responsive supply chain management and regional production capacity.
Government of India	Feb-26	India launched a $1.1 billion, five-year investment program dedicated to the research, development, and manufacturing of biologics and biosimilars. The initiative is designed to bolster domestic biopharmaceutical infrastructure and accelerate the growth of the local manufacturing ecosystem.
Kyowa Kirin	Jun-24	Kyowa Kirin announced a $530 million investment to establish a new North American biologics manufacturing facility. The project is focused on expanding production capacity for specialized biologic therapies, particularly those targeting rare and serious disease categories.
Samsung Biologics	Sep-25	Samsung Biologics secured a $1.3 billion contract manufacturing agreement with a U.S.-based pharmaceutical partner running through 2029. This long-term contract reinforces the high market demand for the company’s large-scale CDMO services and contributes to its revenue and capacity utilization strategy.
Altruist Biologics	Apr-26	Altruist Biologics received its first commercial-scale manufacturing license for its Hangzhou site. This regulatory milestone enables the company to initiate large-scale biologics production, substantially strengthening its manufacturing presence and commercial delivery capabilities within China.
Syngene	Mar-24	Syngene inaugurated a new biologics manufacturing facility in India, effectively tripling its overall production capacity. The expansion is aimed at supporting commercial-scale production needs and enhancing the company's ability to service large-scale international biologics projects.
Eli Lilly	May-26	Eli Lilly acquired Engage to integrate proprietary non-viral delivery technology into its genetic medicine platform. The deal addresses critical technical barriers in the development of genetic therapeutics, aligning with the company's strategy to enhance its pipeline of advanced biologic medicines.